# Lucia Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lucia-bio-pty

- Industry: Biotechnology
- Headquarters: Australia
- Website: www.lucia.bio
- Total disclosed funding: $2M
- Latest round: Seed (Aug 18, 2025)
- Investors on record: 2

## About

Based in Queensland, Australia, and founded in 2024 by Tom McCarthy, Lucia Bio Pty Ltd operates as a a Molecule to Medicine (MTM) portfolio biotechnology company. In August 2025, Lucia Bio Pty Ltd raised USD 2 million in seed funding from Uniseed and UniQuest Limited. Lucia Bio develops next-generation selective spleen tyrosine kinase (Syk) inhibitors aimed at treating immune-mediated diseases. Lucia Bio engages in the development of its lead candidates—QED-701 and QED-121. These molecules are designed to address neuroinflammatory disorders and peripheral autoimmune conditions by targeting Syk, a clinically validated node in human immunology. QED-701 is advancing through toxicology studies for neurodegenerative-related inflammation, while QED-121 is progressing through Chemistry, Manufacturing and Controls (CMC) activities to support clinical trial readiness for autoimmune indications. The company will use the funding to advance QED-701 and QED-121 toward clinical studies and expand their use from neuroinflammation to autoimmune diseases.

## Funding rounds

- Seed, Aug 18, 2025, $2M — Uniseed, UniQuest Limited

## Investors

- Uniseed (https://capitalatlas.ai/funds/uniseed) — Seed
- UniQuest Limited — Seed